Compare HIX & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIX | CUVL |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Finance/Investors Services | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.3M | 374.2M |
| IPO Year | 1998 | N/A |
| Metric | HIX | CUVL |
|---|---|---|
| Price | $3.48 | $4.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 365.5K | 5.3K |
| Earning Date | 01-01-0001 | 08-27-2026 |
| Dividend Yield | ★ 13.14% | 0.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.47 |
| Revenue Next Year | N/A | $6.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.34 | $4.88 |
| 52 Week High | $4.33 | $8.20 |
| Indicator | HIX | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 42.09 |
| Support Level | $3.46 | $4.91 |
| Resistance Level | $4.04 | $5.40 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 79.41 | 36.88 |
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.